DNA damage in blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: European Journal of Nuclear Medicine and Molecular Imaging, 46, 8, S. 1723-1732
- Event
-
Veröffentlichung
- (where)
-
Augsburg
- (who)
-
Universität Augsburg
- (when)
-
2019
- Event
-
Veröffentlichung
- (where)
-
Berlin [u.a.]
- (who)
-
Springer
- (when)
-
2019
- Creator
-
Schumann, Sarah
Scherthan, Harry
Lapa, Constantin Frederik Victor
Serfling, Sebastian
Muhtadi, Razan
Lassmann, Michael
Eberlein, Uta
- DOI
-
10.1007/s00259-019-04317-4
- URN
-
urn:nbn:de:bvb:384-opus4-629530
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:56 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Schumann, Sarah
- Scherthan, Harry
- Lapa, Constantin Frederik Victor
- Serfling, Sebastian
- Muhtadi, Razan
- Lassmann, Michael
- Eberlein, Uta
- Universität Augsburg
- Springer
Time of origin
- 2019
Other Objects (12)
![DNA damage in blood leukocytes of prostate cancer patients undergoing PET/CT examinations with [68Ga]Ga-PSMA I&T](/assets/placeholder/searchResultMediaUnknown.png)
DNA damage in blood leukocytes of prostate cancer patients undergoing PET/CT examinations with [68Ga]Ga-PSMA I&T
PSMA inhibitor-based radiopharmaceuticals for diagnosis and therapy of prostate cancer
PSMA-targeting radiopharmaceuticals for prostate cancer Therapy: recent developments and future perspectives
Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
Induction and repair of DNA double-strand breaks in blood leukocytes of prostate cancer patients during Lu-177-PSMA therapy [Abstract]
Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer
Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer - combination strategies
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
Detection rate of 68Ga-PSMA Ligand PET/CT in patients with recurrent prostate cancer and androgen deprivation therapy
DNA damage in blood leukocytes of prostate cancer patients undergoing PET/CT examinations with [68Ga]Ga-PSMA I&T
PSMA inhibitor-based radiopharmaceuticals for diagnosis and therapy of prostate cancer
PSMA-targeting radiopharmaceuticals for prostate cancer Therapy: recent developments and future perspectives
Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
Induction and repair of DNA double-strand breaks in blood leukocytes of prostate cancer patients during Lu-177-PSMA therapy [Abstract]
Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer
Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer - combination strategies
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
Detection rate of 68Ga-PSMA Ligand PET/CT in patients with recurrent prostate cancer and androgen deprivation therapy
DNA damage in blood leukocytes of prostate cancer patients undergoing PET/CT examinations with [68Ga]Ga-PSMA I&T
PSMA inhibitor-based radiopharmaceuticals for diagnosis and therapy of prostate cancer
PSMA-targeting radiopharmaceuticals for prostate cancer Therapy: recent developments and future perspectives
Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
Induction and repair of DNA double-strand breaks in blood leukocytes of prostate cancer patients during Lu-177-PSMA therapy [Abstract]
Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer
Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer - combination strategies
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer